Emergent extends BioThrax and R&D agreement with US government
This article was originally published in Scrip
Executive Summary
Emergent Biosolutionshas signed another deal with the US Department of Health and Human Services (HHS) to supply it with a further 14.5 million doses of BioThrax, an adsorbed anthrax vaccine, for the country's strategic national stockpile (SNS). Emergent could earn $364-404 million from the contract, with the higher amount dependant on the company delivering a product with a four-year expiry date.